Medivation, Inc. (MDVN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
80.23-0.04 (-0.05%)
At close: 4:00 PM EDT

80.25 0.02 (0.02%)
After hours: 4:01 PM EDT

People also watch:
BMRNALXNREGNSGENINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open80.31
Prev Close80.27
Bid80.25 x 12000
Ask80.26 x 5500
Day's Range80.20 - 80.36
52wk Range26.41 - 80.67
1y Target EstN/A
Market Cap13.31B
P/E Ratio (ttm)-74.22
Beta1.33
Volume13,961,052
Avg Vol (3m)3,025,346
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Tesla takes fast to new level, Pfizer inks another deal, Fitbit pops after trade secrets win
    Editor's Pick
    Yahoo Finance6 hours ago

    Tesla takes fast to new level, Pfizer inks another deal, Fitbit pops after trade secrets win

    Pfizer (PFE) shares remain in the spotlight. The US drug maker that bought cancer drug firm Medivation (MDVN) just a couple of days ago is now buying part of AstraZeneca’s (AZN) antibiotics business. FitBit (FIT) shares got a healthy pop ahead of the open after a US trade judge ruled late Tuesday that the maker of wearable fitness trackers did not steal trade secrets from rival Jawbone.

  • Why no other drug maker was able to close the Medivation deal
    Editor's Pick
    Nicole Sinclair2 days ago

    Why no other drug maker was able to close the Medivation deal

    On Monday, Medivation (MDVN), which owns Xtandi, confirmed it was being acquired by Pfizer (PFE) for $14 billion. This comes just months after Sanofi (SNY) approached Medivation in a hostile deal, going public with its offer and beginning a process to replace the company’s board. Sanofi lost out on its bid to Pfizer, which was willing to pay up and fold Medivation into its oncology franchise.

  • Dear Pfizer, Stop Overpaying for Acquisitions!
    Motley Fool27 minutes ago

    Dear Pfizer, Stop Overpaying for Acquisitions!

    M&A is a big part of Pfizer's growth strategy, but the company hasn't done a very good job of reasonably pricing its purchases.